The Life Science business of Merck KGaA, Darmstadt, Germany Becomes a Trusted Partner of the Flemingsberg Science Foundation

Flemingsberg, 2025-06-23

The Life Science business of Merck KGaA, Darmstadt, Germany, and Flemingsberg Science Foundation collaborate to promote Life Science sector in Flemingsberg. This strategic partnership aims to strengthen development of ATMP (Advanced Therapy Medicinal Products).

Given the rapid development of ATMP (Advanced Therapy Medicinal Products) in Flemingsberg, the foundation seeks to create a strong support network for individuals and companies within the Life Science sector. Through this partnership with the Life Science business of Merck KGaA, Darmstadt, Germany, Flemingsberg Science Foundation is taking another significant step towards building a robust infrastructure for innovation and growth in the region.

“Together with the foundation and other partners, we will contribute by identifying growth opportunities, infrastructure needs, and investment areas that can further develop the ATMP environment in Flemingsberg. Through our presence in Flemingsberg, we can efficiently and effectively meet the specific needs of companies and organizations within the ATMP sector.” – Gianluca Tagliapietra, Senior VP Commercial SLS EMEA, the Life Science business of Merck KGaA, Darmstadt, Germany.

“The Life Science business of Merck KGaA, Darmstadt, Germany provides cutting-edge technology, expertise, and strategic partnerships that strengthen the life science cluster in Flemingsberg in multiple ways, both directly and in the long term. Their presence creates opportunities for our companies and organizations to benefit from their expertise and enables collaborations through meetings and events. Together with our other trusted partners, they also contribute the knowledge and network we need to continue developing Flemingsberg, as well as the platform ATMP Flemingsberg”. – Johnny Högberg, CEO of the Flemingsberg Science Foundation.

As a trusted partner, the Life Science business of Merck KGaA, Darmstadt, Germany, will, among other things, organize at least three events per year, become a member of Novum Labs – an innovative environment with state-of-the-art laboratory facilities and room for growth – and host workshops, seminars, and panel discussions on regulatory challenges, commercialization, and scientific advancements.

This partnership is part of the initiative to strengthen the growth and establishment of small and medium-sized enterprises (SMEs) in the life science sector in the Stockholm region.

Johnny Högberg
CEO, stiftelsen Flemingsberg Science
johnny.hogberg@flemingsbergscience.se
070 550 12 73

South Korean Game Investors Visited Press Start Game Hub in Flemingsberg

A delegation of investors from some of South Korea’s leading game companies visited Press Start Game Hub in Flemingsberg yesterday, a growing hub for game innovation and entrepreneurship in Europe. The visit was part of an initiative organized by Business Sweden, aimed at strengthening ties between the Swedish and South Korean gaming industries.

The Flemingsberg Science Foundation welcomes Angela Hoyer as the new Networks and Event Manager

With a background as a researcher at Karolinska Institutet and experience from academia, industry, and networking, Angela Hoyer, the new Networks and Event Manager at the Flemingsberg Science Foundation, is passionate about developing the life science sector. In her new role, Angela looks forward to creating meeting places where collaborations can grow, while also contributing to Flemingsberg’s continued development as a strong international hub for research and innovation.

A national resource for tomorrow’s treatments – Karolinska ATMP Center is now inaugurated

With a clear message of hope for the future and a powerful spirit of collaboration, the Karolinska ATMP Center in Flemingsberg was inaugurated at the end of August. The center is a collaboration between Karolinska Institutet and Karolinska University Hospital and will serve as a national resource for the production of advanced therapies (ATMPs), where research, clinical trials, and treatments work seamlessly together to deliver groundbreaking therapies to patients.

Go to Top